Syntara Ltd (AU:SNT) — Market Cap & Net Worth
Market Cap & Net Worth: Syntara Ltd (SNT)
Syntara Ltd (AU:SNT) has a market capitalization of $28.89 Million (AU$40.83 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23929 globally and #943 in its home market, demonstrating a 4.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syntara Ltd's stock price AU$0.03 by its total outstanding shares 1633033305 (1.63 Billion). Review how much debt does Syntara Ltd carry to assess the company's total debt and financial obligations.
Syntara Ltd Market Cap History: 2015 to 2026
Syntara Ltd's market capitalization history from 2015 to 2026. Data shows change from $415.97 Million to $28.89 Million (-18.60% CAGR).
Syntara Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syntara Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.41x
Syntara Ltd's market cap is 5.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $323.53 Million | $14.34 Million | -$16.46 Million | 22.57x | N/A |
| 2017 | $294.65 Million | $13.29 Million | -$18.35 Million | 22.18x | N/A |
| 2018 | $306.20 Million | $7.28 Million | $6.43 Million | 42.05x | 47.64x |
| 2019 | $184.88 Million | $5.68 Million | -$20.06 Million | 32.57x | N/A |
| 2020 | $107.46 Million | $7.03 Million | -$13.94 Million | 15.29x | N/A |
| 2021 | $138.66 Million | $7.43 Million | -$2.97 Million | 18.67x | N/A |
| 2022 | $70.48 Million | $5.76 Million | -$1.94 Million | 12.23x | N/A |
| 2023 | $23.11 Million | $5.76 Million | -$11.36 Million | 4.01x | N/A |
| 2024 | $92.44 Million | $5.43 Million | -$15.14 Million | 17.03x | N/A |
| 2025 | $40.44 Million | $7.48 Million | -$7.92 Million | 5.41x | N/A |
Competitor Companies of SNT by Market Capitalization
Companies near Syntara Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Syntara Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Syntara Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Syntara Ltd's market cap moved from $415.97 Million to $ 28.89 Million, with a yearly change of -18.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$28.89 Million | -28.57% |
| 2025 | AU$40.44 Million | -56.25% |
| 2024 | AU$92.44 Million | +300.00% |
| 2023 | AU$23.11 Million | -67.21% |
| 2022 | AU$70.48 Million | -49.17% |
| 2021 | AU$138.66 Million | +29.03% |
| 2020 | AU$107.46 Million | -41.88% |
| 2019 | AU$184.88 Million | -39.62% |
| 2018 | AU$306.20 Million | +3.92% |
| 2017 | AU$294.65 Million | -8.93% |
| 2016 | AU$323.53 Million | -22.22% |
| 2015 | AU$415.97 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Syntara Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.89 Million USD |
| MoneyControl | $28.89 Million USD |
| MarketWatch | $28.89 Million USD |
| marketcap.company | $28.89 Million USD |
| Reuters | $28.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more